Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model

Author： Engin-Ustun Yaprak   Yılmaz Saynur   Timur Hakan   Ustun Yusuf   Moraloglu Ozlem   Deveer Ruya   Yılmaz Nafiye  

Publisher： Informa Healthcare

ISSN： 1473-0766

Source： Gynecological Endocrinology, Vol.29, Iss.9, 2013-09, pp. : 851-854

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Cabergoline as treatment of ovarian hyperstimulation syndrome: a review

By Kalampokas Theodoros   Creatsas George   Kalampokas Emmanouil  

Gynecological Endocrinology, Vol. 29, Iss. 2, 2013-02 ,pp. : 98-100

Informa Healthcare

Access to resources Recommend Favorite

Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study

By lvarez Claudio   Alonso-Muriel Isabel   Garca Gabriela   Crespo Juana   Bellver Jos   Simn Carlos   Pellicer Antonio  

Human Reproduction, Vol. 22, Iss. 12, 2007-12 ,pp. : 3210-3214

Oxford University Press

Access to resources Recommend Favorite

Involvement of ovarian kinin-kallikrein system in the pathophysiology of ovarian hyperstimulation syndrome: studies in a rat model

By Ujioka T   Matsuura K   Tanaka N   Okamura H  

Human Reproduction, Vol. 13, Iss. 11, 1998-11 ,pp. : 3009-3015

Oxford University Press

Access to resources Recommend Favorite

Ovarian hyperstimulation syndrome

By Balen Adam  

Human Fertility, Vol. 10, Iss. 3, 2007-09 ,pp. : 189-189

Informa Healthcare

Access to resources Recommend Favorite

Understanding ovarian hyperstimulation syndrome

By Delbaere Anne   Smits Guillaume   Leener Anne   Costagliola Sabine   Vassart Gilbert  

Endocrine Journal, Vol. 26, Iss. 3, 2005-04 ,pp. : 285-289

Humana Press, Inc

Access to resources Recommend Favorite